Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 444 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR How to Find an Oncologist Who’s an LGBTQ+ Ally: An Expert... April 14, 2021 Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk... October 1, 2024 Medical Assistant Diagnosed with Breast Cancer While Volunteering as Patient for... May 7, 2021 ESMO Targeted Anticancer Therapies Congress 2021, 1-2 March February 23, 2021 Load more HOT NEWS What Are Biosimilars in Cancer Treatment? EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan Resilience Isn’t About Bouncing Back Sex, intimacy and cancer – That Cancer Conversation
